TY - JOUR
T1 - The serial hemostasis-related changes in patients with cerebral infarction
T2 - comparison between progressing and non-progressing stroke
AU - Ho, Chao Hung
AU - Hu, Han Hwa
AU - Wong, Wen Jang
N1 - Funding Information:
Acknowledgments We thank Mr. Chao-Hsien Chen who orovided most of the technical aids in this study which was supported by grants (NSC 77-0412-B075-51) from the National Science Council, Republic of China.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1989/12/1
Y1 - 1989/12/1
N2 - Serial determinations of beta-thromboglobulin (BTG), platelet factor 4 (PF4), fibrinopeptide A (FPA), anti-thrombin III (ATIII), protein C (PC), fibrin(ogen) degradation product (FDP), FDP D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), and euglobulin lysis time (ELT) were performed in 18 patients with non-progressing stroke and 14 patients with progressing stroke in order to predict the development of progressing stroke. Increasing levels of BTG, PF4 and FDP with frequent fluctuation were noted in both kinds of stroke. Fluctuation of FPA levels was also noted but was less pronounced. PC levels were found to be slightly decreased with fluctuation but the mean was still in the lower normal limit. BTG, PF4 and PC all elevated at the time of deterioration of physical condition in patients with progressing stroke, whereas FPA had no definite change at that time. From out study, we conclude that both platelet activation and coagulation process do occur in both kinds of stroke. But the latter plays a minor role in the formation of thrombosis. The hemostasis change, especially concerning the thrombosis formation, probably plays a role in the development of progressing stroke, but we cannot predict their development even by the detections of the newly known molecular substances appearing in various steps of the hemostatic mechanism. Developtment of new tests for understanding the whole dynamic change of the thrombosis process is necessary for accurate prediction of the progressing stroke in the future.
AB - Serial determinations of beta-thromboglobulin (BTG), platelet factor 4 (PF4), fibrinopeptide A (FPA), anti-thrombin III (ATIII), protein C (PC), fibrin(ogen) degradation product (FDP), FDP D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), and euglobulin lysis time (ELT) were performed in 18 patients with non-progressing stroke and 14 patients with progressing stroke in order to predict the development of progressing stroke. Increasing levels of BTG, PF4 and FDP with frequent fluctuation were noted in both kinds of stroke. Fluctuation of FPA levels was also noted but was less pronounced. PC levels were found to be slightly decreased with fluctuation but the mean was still in the lower normal limit. BTG, PF4 and PC all elevated at the time of deterioration of physical condition in patients with progressing stroke, whereas FPA had no definite change at that time. From out study, we conclude that both platelet activation and coagulation process do occur in both kinds of stroke. But the latter plays a minor role in the formation of thrombosis. The hemostasis change, especially concerning the thrombosis formation, probably plays a role in the development of progressing stroke, but we cannot predict their development even by the detections of the newly known molecular substances appearing in various steps of the hemostatic mechanism. Developtment of new tests for understanding the whole dynamic change of the thrombosis process is necessary for accurate prediction of the progressing stroke in the future.
KW - Cerebral infarction
KW - non-progressing stroke
KW - progressing stroke
KW - serial hemostasis-related changes
UR - http://www.scopus.com/inward/record.url?scp=0024825934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024825934&partnerID=8YFLogxK
U2 - 10.1016/0049-3848(89)90271-5
DO - 10.1016/0049-3848(89)90271-5
M3 - Article
C2 - 2534001
AN - SCOPUS:0024825934
SN - 0049-3848
VL - 56
SP - 635
EP - 647
JO - Thrombosis Research
JF - Thrombosis Research
IS - 5
ER -